Evidence map›Paper›PMID 40837587›Full record

ArticleFrontiers in immunology2025

Case Report: Low pressure hyperbaric oxygen therapy as a potential alternative treatment for chronic inflammatory response syndrome: a case study with notable improvements in fatigue, cognition, and testing.

Kristen L Coletti Giesler

Abstract readCase Reports
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Observational
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Kristen L Coletti GieslerBe-Well Medicine Limited Liability Corporation (LLC), Kenai, AK, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic Inflammatory Response Syndrome (CIRS), a complex condition triggered by environmental exposures such as mold toxins, remains challenging to treat effectively. This case study documents the incidental findings of hyperbaric oxygen therapy (HBOT) as a potential therapeutic intervention for CIRS. A 60-year-old female patient with persistent symptoms and abnormal laboratory markers underwent 40 shallow dive HBOT sessions over 10 weeks. Clinical evaluations included symptom scoring, visual contrast sensitivity (VCS) testing, and biomarker analysis, with pre-treatment tests conducted via Quest Diagnostics and post-treatment tests via LabCorp. Results demonstrated significant improvements: resolution of all 22 reported symptoms, normalization of VCS scores (from 68% to 93%), and notable reductions in inflammatory biomarkers, including TGF-β1 and MMP-9. This case illustrates HBOT's ability to modulate systemic inflammation, improve neurocognitive outcomes, and enhance recovery in patients with complex environmental illnesses. While limited to a single-patient design, this study underscores the need for extensive quantitative research to validate HBOT's efficacy in managing CIRS and similar conditions.

Indexed as

CognitionFatigueHyperbaric OxygenationSystemic Inflammatory Response SyndromeBiomarkersFemaleHumansMiddle AgedTreatment OutcomeBiomarkerschronic inflammatory response syndromecognition impairmentcytokinesfatiguelow dive hyperbaric oxygen

Identifiers

PMID40837587
PMCPMC12361165

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.